Overview
Tetrahydrouridine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Sickle Cell Disease, and Head and Neck Cancer, among others.
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Research Report
A Comprehensive Monograph on Sucralfate (DB00364): Pharmacology, Clinical Utility, and Comparative Analysis
Drug Identification and Physicochemical Properties
Sucralfate is a complex organometallic compound widely utilized for its cytoprotective effects within the gastrointestinal tract. A thorough understanding of its identity, from its intricate chemical structure to its physical formulations, is fundamental to appreciating its unique mechanism of action and clinical applications.
Nomenclature and Classification
The drug is universally known by its generic name, Sucralfate.[1] Chemically, it is a basic aluminum salt of sucrose octasulfate, a definition that hints at its complex nature.[3] Its formal chemical name, reflecting its elaborate structure, is Hexadeca-μ-hydroxytetracosahydroxy]hexadecaaluminum.[1] This intricate nomenclature underscores that sucralfate is not a simple molecule but a large, polymerized complex.
In medical and scientific literature, it is also referred to by several synonyms and Medical Subject Headings (MeSH) terms, including Aluminum Sucrose Sulfate and Basic Aluminum Sucrose Sulfate.[6] Its international nonproprietary names include Sucralfato (Spanish) and Sucralfatum (Latin), indicating its global recognition.[1]
Key identifiers are essential for precise database referencing:
- DrugBank ID: DB00364 [1]
- CAS Number: 54182-58-0 [5]
Pharmacologically, sucralfate is classified as a Small Molecule.[1] Based on its chemical composition, it is categorized as an Aluminum Complex and an Organometallic Compound.[6] Therapeutically, it belongs to the classes of Anti-Ulcer Agents and Gastrointestinal Agents, reflecting its primary clinical use.[6]
Chemical and Structural Information
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2023/04/18 | Phase 1 | Completed | |||
2017/07/31 | Phase 1 | Terminated | |||
2016/07/27 | Early Phase 1 | Completed | Yogen Saunthararajah | ||
2016/07/27 | Early Phase 1 | Completed | Yogen Saunthararajah | ||
2016/07/21 | Phase 1 | Withdrawn | |||
2016/01/26 | Phase 2 | Active, not recruiting | |||
2012/09/14 | Phase 1 | Completed | Yogen Saunthararajah | ||
2011/11/24 | Early Phase 1 | Terminated | |||
2009/12/31 | Phase 1 | Completed | City of Hope Medical Center | ||
2007/08/27 | Phase 1 | Completed | Brian Lally |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.